New keytruda copycat tested in lung cancer patients

NCT ID NCT06268613

First seen Nov 01, 2025 · Last updated May 07, 2026 · Updated 30 times

Summary

This study compares a new drug, SB27, to the approved cancer medicine Keytruda in people with early-stage non-small cell lung cancer who have already had surgery and chemotherapy. The main goal is to see if SB27 stays in the body the same way as Keytruda. About 163 adults will receive one of the three treatments every three weeks for up to 18 cycles.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER STAGE II are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • SB Investigative Site

    Gdansk, Poland

  • SB Investigative Site

    Otwock, Poland

  • SB Investigative Site

    Ansan, South Korea

  • SB Investigative Site

    Busan, South Korea

  • SB Investigative Site

    Daegu, South Korea

  • SB Investigative Site

    Hwasun, South Korea

  • SB Investigative Site

    Incheon, South Korea

  • SB Investigative Site

    Jinju, South Korea

  • SB Investigative Site

    Seongnam, South Korea

  • SB Investigative Site

    Ulsan, South Korea

  • SB Investigative Site

    Jaén, Jaén, Spain

  • SB Investigative Site

    A Coruña, Santiago de Compostela, Spain

  • SB Investigative Site

    Málaga, Spain

  • SB Investigative Site

    Adana, Turkey (Türkiye)

  • SB Investigative Site

    Istanbul, Turkey (Türkiye)

  • SB Investigative Site

    Izmir, Turkey (Türkiye)

  • SB Investigative Site 1

    Suwon, South Korea

  • SB Investigative Site 1

    Ankara, Turkey (Türkiye)

  • SB Investigative Site 2

    Suwon, South Korea

  • SB Investigative Site 2

    Ankara, Turkey (Türkiye)

  • SB Investigative Site 3

    Seoul, South Korea

  • SB Investigative Site 4

    Seoul, South Korea

  • SB Investigative Site 5

    Seoul, South Korea

  • SB Investigative Site 6

    Seoul, South Korea

Conditions

Explore the condition pages connected to this study.